Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADOPT-lung: Adjuvant durvalumab after neoadjuvant chemo-immunotherapy in resectable NSCLC
2023-508773-82-00Phase 3Authorised
- Sponsor
- ETOP IBCSG Partners Foundation
- Start
- Sep 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 10
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Adjuvant durvalumab with Observation (2 arms). Primary endpoint: Disease-free survival in patients without pathologic complete response. Planned start Sep 2024; status: authorised.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-508773-82-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508773-82-00.